The pipeline: Long-acting agents and new drugs. Charles Flexner, MD Johns Hopkins University
|
|
- William Morgan
- 5 years ago
- Views:
Transcription
1 The pipeline: Long-acting agents and new drugs Charles Flexner, MD Johns Hopkins University
2 Do we still need an ARV pipeline?
3 How close are we to having a universal antiretroviral regimen?
4 A universal low-cost ARV regimen? Dolutegravir 50 mg TAF 25 mg 3TC/FTC 300 or 200 mg mg vs mg QD for Atripla
5 What Motivates the ARV Pipeline? Less frequent dosing Once weekly orals Once monthly (or less) injectables/implantables Prevention/PreP Different drugs than used for treatment Off label use once approved Concerns about increased availability of generics TDF/3TC fixed-dose combination as an example
6 HIV Pipeline 2015 Flexner and Saag, Current Opin HIV AIDS 2013
7 HIV Pipeline 2015 Flexner and Saag, Current Opin HIV AIDS 2013
8 New NNRTI s: Why?
9 New NNRTI s: Doravirine
10 Doravirine Pharmacology Once-daily dosing Plasma t ½ hours Drug drug interaction potential: Metabolized via CYP3A4 Not a known CYP inducer or inhibitor No significant food effect Well-tolerated (no apparent CNS toxicity) No QTc prolongation seen Anderson MS et al., Antiviral Ther. 2015: in press
11 Anderson MS et al., Antiviral Ther. 2015
12 HIV Drug Therapy Glasgow Week Efficacy and Safety and Early CNS Tolerability of Doravirine, a Novel NNRTI, with TDF/FTC in ART-Naïve HIV-Infected Patients Josep M. Gatell 1, Javier O. Morales-Ramirez 2, Debbie P. Hagins 3, Melanie Thompson 4, Keikawus Arastéh 5, Christian Hoffmann 6, Sorin Rugina 7, Olayemi Osiyemi 8, Simona Erscoiu 9, Robin Dretler 10, Charlotte Harvey 11, Xia Xu 11, Hedy Teppler 11 for the P007 Study Team 1 Hospital Clinic/IDIBAPS. Univ of Barcelona, Spain; 2 Clinical Research Puerto Rico, San Juan, PR; 3 Chatham County Health Dept, Savannah, GA, USA; 4 AIDS Research Consortium of Atlanta, Atlanta, GA, USA; 5 EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 6 ICH Study Center, Hamburg, Germany; 7 Spitalul Clinic de Boli Infectioase, Constanta, Romania; 8 Triple O Research Institute PA, West Palm Beach, FL, USA; 9 Spitalul Clinic de Boli Infectioase si Tropicale "Dr. Victor Babes," Bucharest, Romania; 10 Infectious Disease Specialists of Atlanta, Decatur, GA, USA; 11 Merck & Co., Inc., Whitehouse Station, NJ, USA Copyright 2014 Merck & Co. Inc. All Rights Reserved.
13 Patients: HIV-1+ ART-naïve HIV RNA 1,000 c/ml; CD4 count 100 cells/µl Protocol 007: Study Schema Part 1 Dose Ranging Phase (N=210) DOR 25 mg (n=41) DOR 50 mg (n=43) DOR 100 mg (n=42) DOR 200 mg (n=41) EFV 600 mg (n=43) 100 mg 100 mg 100 mg Part 1 Extension Phase DOR 100 mg Continue EFV Wk 24 Wk 36 Wk 48 Wk 96 P007 Week 24 Analysis for Dose Selection 6 Antiretroviral activity of DOR comparable to EFV Favorable safety profile at all doses Doravirine 100 mg selected for further development Part 1 DOR patients began switch to 100 mg at Week J Morales-Ramirez, et al. CROI 2014 [Abstr 92LB]. 13 Copyright 2014 Merck & Co. Inc. All Rights Reserved.
14 Virologic Response by Screening RNA Ad hoc analysis, Week 48 (Observed Failure) 100,000 c/ml >100,000 c/ml N: Gatell et al., Glasgow 2014 Copyright 2014 Merck & Co. Inc. All Rights Reserved.
15 Primary Safety Comparison: CNS Events, All Causality Parts 1 & 2 Combined, Week 8 Significantly fewer patients on DOR had 1 CNS event by week 8 (p<0.001) Suicidal ideation 0 0,9 % of Patients with 1 CNS Event Attention disturbance Somnolence 0 0 0,9 2,8 DOR 100 mg (N=108) EFV (N=108) Δ (95% CI) 22.2% 43.5% (-33.2, -8.8) Depression Hallucination Nightmares 1,9 0,9 2,8 0,9 5,6 8,3 Efavirenz Doravirine 100 mg Abnormal dreams 5,6 16,7 Insomnia 2,8 6,5 Dizziness 9,3 27,8 Gatell et al., Glasgow % of patients with 1 event Copyright 2014 Merck & Co. Inc. All Rights Reserved.
16 Future Directions for Doravirine 100 mg daily dose selected for future study Phase 3 trials well underway New FDC s in development Positioning: First-line? Second-line? Something else?
17 New InSTI s: Cabotegravir Both oral and long-acting?
18 LATTE-1 Study Results Margolis et al., Lancet Infect Dis 2015; 15: 1145
19 LATTE-2 Study Design Margolis and Boffito, Current Opinion HIV AIDS 2015; 4: 246
20 LATTE-2 Study Design Margolis and Boffito, Current Opinion HIV AIDS 2015; 4: 246
21 LA/ER Drugs: What s next?
22 LA/ER Drugs: Broadly-neutralizing monoclonal antibodies
23 Caskey et al., New Engl J Med 2016; 375: 2019
24 Effect of VRC01 on Viral Rebound Bar et al., New Engl J Med 2016; 375: 2037
25 Effect of VRC01 on Viral Rebound Bar et al., New Engl J Med 2016; 375: 2037
26 Effect of VRC01 on Viral Rebound Bar et al., New Engl J Med 2016; 375: 2037
27 Effect of VRC01 on Viral Rebound Bar et al., New Engl J Med 2016; 375: 2037
28 Bar et al., New Engl J Med 2016; 375: 2037
29 Broadly-neutralizing monoclonal antibodies Potential advantages Humanized, well-tolerated Extendification possible LA version of VRC01 in clinical development May induce beneficial host cell-mediated immunity ADCC responses Use in prevention applications, PrEP Potential disadvantages Expensive Intravenous route of administration Pre-existing resistance commonplace Select for resistance viruses
30 LA ARV s: New technologies
31 LA ARV Implants Tenofovir Alafenamide M Gunawardana et al., Antimicrob Agents Chemother 2015; 59: 3913
32 LA ARV Implants Tenofovir Alafenamide M Gunawardana et al., Antimicrob Agents Chemother 2015; 59: 3913
33 M K P la s m a C o n c e n tra tio n (n g /m L ) MK-8591 (EFdA) Implant Formulations Release Effective Drug Levels for >180 days F o r m u la tio n # 1 (n = 4 ) F o r m u la tio n # 2 (n = 4 ) T im e (d a y s ) >180-day extended release from solid state formulations after a single injection in rats. Data suggest the potential to provide coverage for durations up to 1 year. - Grobler JA et al. CROI, 2/22-2/25, 2016, Boston, MA 33
34 Long Acting ARV Implants Potential advantages over injectables Removable More consistent and predictable drug release PK not dependent on injection site May remain in place for years (inert, non-degradable subcutaneous versions) Potential disadvantages over injectables Specialized device required for insertion Minor surgical procedure to remove Regulated as both a drug and a device Difficulty moving to a generic marketplace
35 LA ARV s: Gaps and Opportunities
36 Long Acting ARV s: Knowledge Gaps Oral lead-in required? Minimum injection frequency? Number of injections/volume allowed per dose? How many drugs in the regimen? How to manage toxicity? What to do about missed doses? How to quit? How to manage the long PK tail?
37 Long Acting ARV s: Opportunities Developing investigational agents targeted specifically for LA regimens Cabotegravir as a paradigm New technologies Implants Use of physiologically-based pharmacokinetic (PBPK) modeling to predict human pharmacokinetics, required potency, and release rates of new formulations
38
39 Acknowledgements Johns Hopkins University Jane McKenzie-White Jennifer Robinson Caren Freel Meyers Chelsea Westminster, London Marta Boffito Division of AIDS, NIAID Daniella Livnat Peter Kim Univ. of Liverpool Andrew Owen Marco Siccardi Steve Rannard UNMC Sue Swindells Howard Gendelman FUNDING SOURCES NIAID Bill and Melinda Gates Foundation Clinton Health Access Initiative
Efficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
Efficacy and Safety of Doravirine 1mg QD vs Efavirenz 6mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla,
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationLong-Acting Antiretrovirals for HIV
Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City Disclosures None Single Tablet
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationFuture Perspectives for Delivery of Antiretroviral Drugs
Future Perspectives for Delivery of Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie,
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More information4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections
Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationNew Delivery Systems and Long Acting Antiretroviral Drugs
New Delivery Systems and Long Acting Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Prague October 2018 Disclosures Honoraria received for advisory boards
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More information23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationRoy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York
Antiretroviral Therapy: Investigational New Drugs and New Strategies Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York FORMATTED: MM/DD/YY Antiretroviral
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationv Dr Anton Pozniak Chelsea and Westminster Hospital, London Injectable ARVs a S.W.O.T Analysis
18 th Annual Resistance and Antiviral Therapy Meeting v Dr Anton Pozniak Chelsea and Westminster Hospital, London Thursday 18 September 2014, Royal College of Physicians, London Injectable ARVs a S.W.O.T
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationPharmacology Lessons from Chemoprophylaxis Studies. Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK
Pharmacology Lessons from Chemoprophylaxis Studies Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK Pre tenofovir generation 1996-2009 PK did not inform trials
More informationThe injectables: a new silver bullet?
The injectables: a new silver bullet? Geneva October 6 Francois Venter Wits Reproductive Health and HIV Institute Thanks Clinical Care Options, Helen Rees, Joe Eron, Wits RHI sex worker team Disclosures
More informationCROI 2016: Top Ten for Clinicians
Hynes Convention Center. Boston, MA; US. Feb 22-25, 2016 CROI 2016: Top Ten for Clinicians Josep M Llibre Hospital Universitari Germans Trias i Pujol Fundació Lluita contra la SIDA Badalona, Barcelona
More informationDr Manisha Yapa. Chelsea and Westminster Hospital, London. 19 th Annual Conference of the British HIV Association (BHIVA)
19 th Annual Conference of the British HIV Association (BHIVA) Dr Manisha Yapa Chelsea and Westminster Hospital, London 16-19 April 2013, Manchester Central Convention Complex The impact of switching to
More informationMucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials. Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA
Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA Overview A brief history of oral/la PrEP research Integration
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationMiss Jane Rowlands. Chelsea and Westminster Hospital, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Miss Jane Rowlands Chelsea and Westminster Hospital, London 1-4 April 2014, Arena and Convention Centre Liverpool Multi-centre open-label study of switching
More informationClinical Pharmacology Related Considerations.
Clinical Pharmacology Related Considerations. David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie, BMS,
More informationInvestigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents
Investigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents Joseph J. Eron MD Professor of Medicine University of North Carolina Chapel Hill, North Carolina Learning Objectives
More informationInjectable Antiretrovirals The Promise and the Peril. Ian McGowan MD PhD FRCP University of Pittsburgh, PA, USA Cape Town, 6 th October, 2015
Injectable Antiretrovirals The Promise and the Peril Ian McGowan MD PhD FRCP University of Pittsburgh, PA, USA Cape Town, 6 th October, 2015 The Promise Long Acting Formulations Have been used to improve
More informationLong Acting ART for Treatment and PrEP
Long Acting ART for Treatment and PrEP Anton Pozniak MD FRCP Consultant Physician Disclosures I have received honoraria, travel sponsorship and research grants from: Gilead Sciences Janssen MSD ViiV Healthcare
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationNuevos fármacos an/retrovirales
Nuevos fármacos an/retrovirales Pere Domingo Malal/es Infeccioses Hospitals Universitaris Arnau de Vilanova & Santa María IRB Lleida Universitat de Lleida pdomingo@gss.scs.es La escasez persiste... Combinec/n:
More informationCan we make first line ART better?
Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationSwitching strategies and ARV treatment costs
February 2014 Switching strategies and ARV treatment costs Josep M Llibre/Bonaventura Clotet Fundació Lluita contra la SIDA Hosp Univ Germans Trias i Pujol Badalona Rationale. Spain is under a huge economic
More informationLong-acting Treatment with Antiretrovirals
Long-acting Treatment with Antiretrovirals Saye Khoo, University of Liverpool, UK Declaration of Interests www.hiv-druginteractions.org & www.hep-druginteractions.org Receives sponsorship from AbbVie,
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationPurpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation
ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationSafety of Current Antiretroviral Therapy on the CNS Scott Letendre, M.D.
Safety of Current Antiretroviral Therapy on the CNS Scott Letendre, M.D. Professor of Medicine and Psychiatry University of California, San Diego Disclosures Research funds were paid to UC San Diego on
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationNext Generation PrEP? Injectable & Implantable ARVs
Next Generation PrEP? Injectable & Implantable ARVs Craig W. Hendrix, MD Wellcome Professor & Director, Clinical Pharmacology Johns Hopkins University Objectives Describe alternative formulations to improve
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationNew options for new and old patients. Antonella Castagna
New options for new and old patients Antonella Castagna Disclosures I have received funding for Advisory Boards, Speaker Panels and for preparation of educational materials from the following: Gilead Sciences
More informationLong-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018
Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Global HIV Statistics 2017 People living with HIV in 2016 New HIV infections
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationCan we make first line ART better?
Can we make first line ART better? Dr David Stead Treatment Optimization HIV Clinicians Society Workshop 25 November 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationEpidemiology. Update From the 2019 Conference on Retroviruses and Opportunistic Infections. Learning Objectives
Slide 1 of 51 Update From the 2019 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University Atlanta, Georgia
More informationAntiretroviral Treatment: What's in the Pipeline
Antiretroviral Treatment: What's in the Pipeline Joseph P. McGowan, MD, FACP, FIDSA Professor of Medicine Hofstra North Shore-LIJ School of Medicine October 14, 2015 Which describes best how HIV Maturation
More informationNUEVOS ENFOQUES TERAPEUTICOS
NUEVOS ENFOQUES TERAPEUTICOS -11ºC Daniel Podzamczer Unidad VIH. S Enf. Infecciosas Hospital Universitari de Bellvitge L Hospitalet. Barcelona AGENDA ART simplification QD regimen: RAL Bitherapy: DRVr/RAL
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationIn Silico Pharmacokinetic/Pharmacodynamic Simulation Of Long Acting Tenofovir Injectable Formulation For Pre-exposure Prophylaxis Strategies
In Silico Pharmacokinetic/Pharmacodynamic Simulation Of Long Acting Tenofovir Injectable Formulation For Pre-exposure Prophylaxis Strategies Paul Curley, Darren Moss, Rajith K R Rajoli, James Hobson, Caren
More informationBHIVA Best of CROI Feedback Meetings
BHIVA Best of CROI Feedback Meetings London Birmingham Haydock Newcastle Cardiff Wakefield Edinburgh BHIVA Best of CROI Feedback Meetings 2016 New drugs Dr David Asboe Chelsea and Westminster Hospital,
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationHIV life cycle revisited: What s new in basic science? Theresa Rossouw
HIV life cycle revisited: What s new in basic science? Theresa Rossouw Outline of the Presentation Lifecycle overview New drugs & therapies Cell entry Co-receptor binding Attachment Keeping it Simple
More informationWhat s in the Biomedical Prevention Pipeline
What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationDolutegravir Attributes
Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1
More informationNew Drugs in Development Are We Ready for Long-Acting ART?
New Drugs in Development Are We Ready for Long-Acting ART? Melanie A. Thompson, MD Principal Investigator AIDS Research Consortium of Atlanta Atlanta, Georgia Learning Objectives After attending this presentation,
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationEuropean Guidelines. for the Clinical Management and Treatment of HIV Infected Adults
European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationInjectable Pre-exposure Prophylaxis
Injectable Pre-exposure Prophylaxis Myron S. Cohen, MD Yeargan-Bate Eminent Professor Medicine, Microbiology and Epidemiology Director, Institute for Global Health & Infectious Diseases Transmission of
More informationHIGH VIRAL LOAD AND TREATMENT RESPONSE
16 th Annual Resistance and Antiviral Dr Bonaventura Clotet Hospital Germans Trias i Pujol, Barcelona, Spain Thursday 20 September 2012, Wellcome Collection Conference Centre, London HIGH VIRAL LOAD AND
More informationCADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs
CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs Meg Doherty, Treatment and Care Coordinator WHO HQ Outline What s new in ARV Guidelines Drug optimisation
More informationThe Prevention Landscape for Women: Yesterday, Today and Tomorrow. Nyaradzo M. Mgodi (MBChB, MMed) MTN Regional Meeting September 25, 2018
The Prevention Landscape for Women: Yesterday, Today and Tomorrow Nyaradzo M. Mgodi (MBChB, MMed) MTN Regional Meeting September 25, 2018 Despite global progress in the last decade, women still bear a
More informationHIV IS NOT OVER. Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Learning Objectives
Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Davey M. Smith, MD, MAS Professor of Medicine University of California San Diego San Diego, California Learning Objectives
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationEffects of Gender, Race, Age & BMI on the Pharmacokinetics of Long-Acting Rilpivirine (RPV-LA) after a Single IM Injection in HIV negative subjects.
Effects of Gender, Race, Age & BMI on the Pharmacokinetics of Long-Acting Rilpivirine (RPV-LA) after a Single IM Injection in HIV negative subjects. Laura Else 1, Akil Jackson 2, Deidre Egan 1, Zeenat
More informationClinical considerations in switching antiretroviral therapy
Clinical considerations in switching antiretroviral therapy David Jilich Department of Infctious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital 4th CEE Meeting
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationTreatment and Care: Product portfolio
Treatment and Care: Product portfolio Dr Paula Munderi MRC/UVRI Uganda Research Unit on AIDS EDCTP Stakeholder Meeting on HIV/AIDS 3-4 September 2013 Summary Brief overview HIV Treatment Pipeline Key Questions
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationLong-Acting Antibodies and Drugs as HIV Prevention Agents. David D. Ho, M.D.
Long-Acting Antibodies and Drugs as HIV Prevention Agents David D. Ho, M.D. the The HIV/AIDS pandemic rages on Key statistics from UNAIDS: 35M dead; 35M living with HIV 2.3M new infections a year or 6,300
More informationWhat more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings?
What more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings? Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationPatient Forecasts for Pipeline ARVs: Adults
Patient Forecasts for Pipeline ARVs: Adults Presented at: WHO/UNAIDS Annual Meeting with ARV Manufacturers and Stakeholders March 19-20, 2015 Vineet Prabhu Market Intelligence Team, CHAI HIV Access Program
More information